Samir Parekh, MBBS
- PROFESSOR | Medicine, Hematology and Medical Oncology
- PROFESSOR | Oncological Sciences
Specialties:Hematology-Oncology, Cancer (Oncology)
Research Topics:Computational Biology, Drug Resistance, Epigenetics, Lymphoma, Transcriptional Activation and Repression
Dr. Samir Parekh, MD is Professor (with tenure) of Medicine (Hematology and Medical Oncology) and Oncological Sciences and Director of Translational Research in Myeloma at the Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai.
Dr. Parekh's research focuses on the pathogenesis of hematological malignancies and development of individualized, precision-medicine therapies for these malignancies. His lab uses an integrated systems biology approach to study genome-wide methylation, gene expression and DNA sequence variation to understand pathogenesis, develop biomarkers and guide personalized therapy in B cell malignancies, particularly Multiple Myeloma and Non-Hodgkin's lymphoma.
Dr. Parekh has served on numerous review and advisory committees. He has successfully secured several federal and foundation grants and has authored multiple peer-reviewed publications.
American Board of Internal Medicine
- Multiple Myeloma
Multi-Disciplinary Training AreasCancer Biology [CAB], Genetics and Genomic Sciences [GGS], Pharmacology and Therapeutics Discovery [PTD]
MBBS, K J Somaiya Medical College
Residency, Internal Medicine, Cook County Hospital
Fellowship, Hematology-Oncology, Montefiore Medical Center /Albert Einstein College of Medicine
Young Investigator Award
Young Investigator Travel Award
First Overall and Highest Rank in General Internal Medicine
Integrative Genomics for Drug repositioning in Myeloma
With the advent of next-generation sequencing, we have been systematically developing and studying the application of integrative genomics (including methylation, gene expression and exome sequencing) to guide personalized repurposing of FDA approved drugs to overcome chemotherapy resistance in B cell malignancies like non-Hodgkins Lymphoma and Multiple Myeloma. I have an ongoing IRB approved clinical trial for genomic signature guided therapeutic selection in collaboration with Drs. Jagannath and Schadt, Dean for Precision Medicine and the Jean C. and James W. Crystal Professor of Genomics at the Icahn School of Medicine at Mount Sinai.
Mantle Cell Lymphoma (MCL)
MCL is a rare and incurable non-Hodgkins lymphoma whose pathogenesis is not clearly understood. The SOX11 transcription factor is overexpressed in the majority of Mantle cell lymphomas. We identified the direct DNA binding targets of SOX11 in several oncogenic pathways using ChIP-sequencing and functional genomics and have now developed an inducible mouse model of SOX11 overexpression that recapitulates the MCL phenotype. We are developing anti-SOX11 small molecules with structural biologist Dr. Aneel Aggarwal at Mount Sinai that could be applicable in MCL and other SOX11 expressing tumors like lung cancer, ovarian cancer and glioma.
Visit the Parekh Laboratory